Gapping down
In reaction to earnings/guidance:
- RGS -0.9%
Other news:
- LPCN -18.8% (provides regulatory update for TLANDO; FDA needs additional time to complete review of NDA)
- PRVB -9.4% (initiates Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015, an anti-interleukin-15 monoclonal antibody, in adult celiac patients)
- NIO -8.2% (prices offering of 88,500,000 American depositary shares at a price of $17.00 per ADS)
- AVYA -4.8% (files for 22,123,022 share common stock offering by selling shareholder)
- ABUS -4.3% (files for $200 mln mixed securities shelf offering)
- MYOK -1.2% (presents results from Phase 3 EXPLORER-HCM clinical trial)
Analyst comments:
- BIGC -12.3% (initiated with an Underweight at Morgan Stanley; tgt $52)
- NPTN -2.3% (downgraded to Hold from Buy at Needham)
- MTN -0.6% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)